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Summary The antitumour activity of flavone acetic acid (FAA) was evaluated against two human colorectal
carcinoma (HCC) lines, HCC-P2988 and HCC-M1410, transplanted into nude mice. On repeated i.v. injection
of 200mgkg-1 every 4 days FAA was moderately active against the s.c. growing HCC-P2988. HCC-M1410
transplanted s.c. was almost unresponsive in the same experimental conditions. In contrast, FAA
(200mgkg-' i.v. every 4 days, repeated three times) significantly reduced liver tumour colonies produced by
the HCC-M1410 cells injected intrasplenically into nude mice.
These findings suggest that FAA has potential activity against human colorectal carcinoma, particularly
against liver metastases.
Flavone acetic acid (FAA, NSC 347512) is a new antitumour
compound under early clinical investigation in Europe and
USA. Considerable interest in this drug derives from
preclinical observations that, in contrast to most available
anticancer agents, FAA is more effective on slow growing
solid tumours (e.g., mouse colon 38 adenocarcinoma) than
on rapidly proliferating leukemias (e.g., L1210, P388)
(Corbett et al., 1986; Bibby et al., 1987; Plowman et al.,
1986). In addition FAA shows no bone marrow toxicity
which is the most frequent drawback of antineoplastic drugs
(Kerr et al., 1986; Zaharko et al., 1986).
Although the effectiveness of FAA has been studied
extensively on a broad spectrum of murine tumours, little
information is available on the activity of the drug against
human tumours transplanted in immunosuppressed or
athymic (T-cell deficient) nude mice. To our knowledge, only
preliminary findings are available showing that a recently
established human melanoma was responsive to FAA, while
two other xenografts, human mammary and human colon
carcinomas evaluated in the subrenal capsule assay, did not
respond (NCI Clinical Brochure, 1985).
To obtain more information on the potential efficacy of
FAA against human colorectal carcinoma (HCC), we
examined its activity against two recently established HCC
transplanted into nude mice (Giavazzi et al., 1986b). The
recent characterization of an experimental nude mouse
model to study the production of liver tumours by HCC
made it possible to explore the activity of this new drug




Six- to 8-week-old male NCr nu/nu mice were obtained
from the National Cancer Institute Animal Program,
Frederick, MD, USA. Mice were age-matched for each
experiment and were housed throughout the experiments in a
laminar flow cabinet under specific-pathogen-free conditions.
Tumour origin
HCC-P2988 was obtained from a surgical biopsy of a
primary rectal carcinoma and established in vitro. The line
was maintained as a monolayer on tissue culture plastic in
Ham's F12 medium (M.A. Bioproducts, Walkersville, MD)
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supplemented with 10% foetal calf serum (Gibco Europe,
Glasgow, Scotland), 5ngml- epidermal growth factor,
5,ugml'- insulin, and 2pgml-1 transferrin (Sigma, St.
Louis, MO). Experiments were made with the cell line within
20-30 passages from its initial culture, Single cell suspensions
were obtained by harvesting the monolayer with 0.125%
trypsin-0.02% EDTA in phosphate buffer saline without
Ca+ + and Mg tt . After washes tumour cells were resuspended
in Ca't and Mgt'-free Hanks' balanced salt solution'
(HBSS) and 2 x 106 cells in a volume of 0.2ml HBSS were
injected in the flank of nude mice. At this cell concentration
all the mice produced a palpable tumour within 15-20 days
from tumour cell injection. HCC-P2988 is a slow-growing
tumour in the nude mouse with a s.c. doubling time of
11 +2.4 days. It is not spontaneously metastatic in the nude
mouse and does not produce liver colonies after intrasplenic
(i.s.) injection.
HCC-M1410 was obtained from a hepatic metastasis of a
patient with a primary rectal tumour (Giavazzi et al., 1986b).
The surgical specimen, dissociated by enzymatic digestion,
was transplanted and maintained in nude mice by i.m.
passage of 1 x 106 single cell suspension. Experiments were
performed between passages 6-10 from the xenograft of the
surgical specimen. A single cell suspension of the HCC-
M1410 growing i.m. was obtained as described previously in
detail (Giavazzi et al., 1986b). Briefly, tumours from a group
of 5 mice were cut into fragments and exposed to 20min
sequential dissociations with collagenase type I (200Uml-)
and DNase (270Uml-1) (Sigma) at 37°C. The cell
suspension was filtered through gauze and 100pm nylon
mesh and washed repeatedly. Five x 105 and 1 x 106 viable
tumour cells, by trypan blue exclusion, in 0.1 ml HBSS were
injected s.c. or i.s. in the nude mouse, as specified in Results.
After s.c. injection of these cell concentrations all mice
developed a palpable tumour within 15 and 10 days
respectively, with a doubling time of 4.5+ 1.1 days. After i.s.
injection mice developed liver colonies and died because of
the liver tumour burden respectively 5 and 4 weeks after
tumour cell injection (Giavazzi et al., 1986a).
Drug
FAA was kindly provided by Dr P. Briet, Lipha, Lyon,
France. The drug was dissolved in 0.3% Na HCO3
immediately before injection and administered at the doses
and schedules specified in Results. Control mice received the
same amount of vehicle. Treatments were given as a slow i.v.
injection over a period of 1 min.
Subcutaneous tumour assay
Therapy was begun when all mice had a palpable tumour
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growing s.c. In one experiment, treatment started 3 days
after HCC-M1410 cell injection. Mice were randomized to
various treatment and control groups. The diameters of
tumours growing s.c. were measured in cm twice a week by
caliper and tumour weight in g was estimated by the
formula, length x width2/2. Mean tumour weights were
plotted against days after tumour cell injection. Percentage
of tumour inhibition on the day indicated was calculated as
100 - [(median tumour weight of treated mice/median
tumour weight of control mice) x 100].
Liver tumour assay
The production of tumour colonies in the livers of nude mice
was examined after i.s. injection of HCC-M1410 cells as
described previously (Giavazzi et al., 1986a). Briefly, in
anaesthetized nude mice an incision was made in the left
flank, carried down through the peritoneal wall and the
spleen was exposed. Cell suspensions in 0.1ml HBSS were
injected into the spleen. Visible 'paling' of the spleen and
lack of bleeding were the criteria for a successful inoculation.
The spleen was then returned into the peritoneal cavity and
the abdominal wall was closed with sutures and the skin
with wound clips.
Autopsies were performed 30 days after tumour cell
injection. The liver and the spleen were removed and
weighed. Livers were fixed in Bouin's solution and the
number of colonies was counted under a dissecting
microscope. Organs with no visible tumour were fixed in
10% buffered formalin and processed for histological
examination.
Statistical analysis
Differences in the numbers of liver colonies, and in tumour
weights and survival times were analyzed by the Mann-
Whitney U test.
Results
Effect ofFAA on primary HCC-P2988
The activity of FAA against the s.c. grafted HCC-P2988 is
shown in Figure 1 and Table I. Treatment was started when
all mice had a palpable, progressively growing tumour.
Injections of 200mgkg- I FAA every 4 days (Q4d x 3)
significantly slowed tumour growth (Figure 1). This was
followed by an increase in survival time for treated mice
(median = 160 days) compared to control mice (median = 127
days). A dose of 100mgkg-1 daily (Qld x 6) or 240mgkg- I
weekly (Q7d x 2) had no effect on tumour growth (Table I).













Table I FAA activity against HCC-P-2988 growing s.c. in nude
mice
Median tumour % tumour
Dosage Toxic weight in g inhibition
(mgkg-1) Schedulea death (range)' on day 60 Pc
Control 0/20 1.18 (0.54-1.72)
100 Qldx6 1/10 0.86 (0.31-2.18) 28 NS
200 Q4dx5 2/10 0.47 (0.06-2.13) 61 <0.05
240 Q7d x 2 1/10 1.02 (0.6-2.62) 12 NS
300 Single 2/10 0.36 (0.13-1.44) 70 <0.01
Nude mice were given 2 x 106 HCC-P-2988 tumour cells s.c.
aTreatment started 15 days after tumour injection when all mice had
a palpable tumour; b60 days after tumour injection mice were
autopsied, tumour removed and weighed; cP compared to control.
single i.v. injection of 300mgkg-1 FAA or injections of
200mgkg-1 every 4 days repeated 5 times (Table I).
However, 300mgkg-1 (single) and 200mgkg-1 (Q4d x 5)
were toxic, causing 20% drug-related deaths. Toxic death
was never associated with weight loss. With 200mgkg-
multiple injections, death occurred at the fourth dose, so we
established the schedule of 200mgkg-1 FAA every 4 days
repeated 3 times for subsequent experiments.
Effect ofFAA on metastatic HCC-M1410
The above treatment (200mgkg-1 FAA, Q4d x 3) was not
active on progressive s.c. growing HCC-M1410 (Figure 2a).
Treatment of the HCC-M1410, transplanted s.c., as early as
3 days after injection delayed tumour appearance (Figure 2b)
but this was not followed by any significant difference in
survival time and none of the mice were tumour free 30 days
after tumour cell injection (data not shown). After i.s.
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. 1 1 1 Days after s.c. transplant 0 10 20 30 40 50 Figure 2 Antitumour activity of FAA against HCC-M1410.
Days after s.c. transplant Panel (a) 1 x 106 HCC-M1410 cells were injected s.c. into nude
Antitumour activity of FAA against HCC-P2988. mice and FAA treatment was started when tumours were
-C-P2988 cells were injected s.c. into nude mice. FAA palpable (arrow). * * control; 0 O 200mgkg-1 FAA
was started when tumours were palpable. The arrow (Q4 x 3). Panel (b) 5 xl10 HCC-M1410 cells were injected s.c.
the first day of FAA treatment. * * control; into nude mice and FAA treatment was started 3 days later
200mgkg -1 FAA (Q4 x 3). (arrow). * 0* control; 0 0 200mgkg -1 FAA (Q4 x3).
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with the liver parenchyma replaced by tumour (Figure 3).
Figure 4 shows that three days after i.s. injection neoplastic
cells were already present in the liver. The i.v. injection of
200mgkg-1 Q4dx3 FAA starting three days after tumour
cell injection significantly reduced the spleen and liver
tumour burden evaluated as organ weight and number of
liver colonies (Table IT). Thirty days after i.s. tumour cell
injection only a few tumour foci were observed in the liver of
FAA treated mice (Figure 3). Three out of 8 mice receiving
5 x 105 HCC-M1410 cells i.s. and FAA therapy were tumour
free in the liver at autopsy (Table II). The absence of liver
tumour deposits was confirmed by histological examination.
Figure 4 Photomicrograph of the liver of a nude mouse 3 days
after i.s. injection of HCC-M1410 tumour cells. Presence of
neoplastic epithelial cells in the liver parenchyma (arrow). x 400.
rigure HCt-MI410 tumour growing in the liver of nude mice
30 days after i.s. injection of 1 x 106 cells. Tumour burden was
extensive in the liver of control mice (top row); tumour colonies
were fewer in the liver of FAA treated mice (bottom row).
Discussion
In this study we found that FAA had moderate activity
against the slow-growing HCC-P2988 transplanted s.c. into
nude mice. HCC-M1410 growing s.c. in nude mice was
almost unresponsive but growing in the liver of nude mice
responded significantly.
HCC-M1410 is a highly malignant tumour that
consistently produces tumour colonies in the liver of nude
mice after i.s. injection (Giavazzi et al., 1986a, b). Treatment
with FAA significantly reduced the liver tumour burden
(Figure 3). FAA treatment was started three days after i.s.
tumour cell injection, by which time single neoplastic cells
and/or small tumour emboli are already present in the liver
and capillary bed. A low tumour burden certainly accounts
for the observed response of HCC-M1410 in the liver.
However, FAA treatment starting three days after s.c.
injection of HCC-M1410 cells only delayed tumour
appearance, with no effect on the rate of tumour growth.
The formation of metastases in a patient with colorectal
tumour represents a major problem in clinical oncology.
About 50% of malignant HCC have already metastasized at
the time of diagnosis, mainly to lymph nodes and liver, and
many more have undetectable micrometastases (August et
al., 1984). The i.s. injection followed by tumour cell
dissemination in the liver may to some extent mimic the
clinical situation and can therefore be used as an
experimental model for evaluating the efficacy of drugs on
liver tumour deposits of colorectal carcinomas.
Significant activity was observed against HCC-M1410
growing in the spleen of nude mice. Whether the effect of
FAA was not directly against liver tumours, but mainly due
to action on the 'primary' tumour growing in the spleen,
with consequently less release into the circulation of tumour
cells eventually colonizing the liver, cannot be established.
However, we have shown previously that splenectomy after
i.s. injection of HCC-M1410 cells did not influence their
ability to grow in the liver (Giavazzi et al., 1986a). We have
also seen that radiolabeled tumour cells reached the liver of
nude mice within a few minutes of injection into the spleen
(Giavazzi et al., 1986a).
Neoplasms can be heterogeneous for many aspects
including drug sensitivity. Differences between primary
tumour and metastases have also been described (Siracky,
1979; Slack & Bross, 1975; Tsuro & Fidler, 1981; Trope,
1975; Von Hoff et al., 1986). Whether liver colonies after i.s.
injection represent selected populations of tumour cells with
a different phenotype such as metastatic ability and drug
sensitivity remains to be shown. Differences in drug
sensitivity associated with the site of tumour growth have
often been explained by a different blood supply and
consequent different drug distribution (Abe et al., 1985;
Donelli et al., 1977; Selby et al., 1979). In this respect it may
be worth recalling that in nude mice the highest
concentrations of FAA were found in the liver (Damia et al.,
1987), suggesting that the better effect against liver tumour
colonies may be due to favourable drug distribution.
Table II Effect of FAA on liver metastases produced by HCC-M 1410 injected intrasplenically into nude mice
Spleen Liver
Median liver
No. cells Mice with tumour/ Weight +s.d. Mice with tumour/ Weight +s.d. colonies
injecteda Treatmentb total mice in g total mice in g (range)
1 x 106 Vehicle 5/5 1.50+0.6 5/5 6.36+2.9 >300 (14->300)
FAA 5/5 0.91 +0.8 5/5 2.41 +o.9d 12 (4-63)e
5x105 Vehicle 10/10 1 +0.8 10/10 3.55+2.8 50 (2->100)
FAA 2/8c 0.23+0.1e 5/8C 1.5 +0.15e 2 (0-20)C
aNude mice were given an intrasplenic injection of viable HCC-M1410 cell suspension and autopsied 4 weeks later; b200mgkg-1 FAA i.v. was given on days 3, 7, 11 after tumour cell injection; cTumour absence was confirmed by
histological examination; dp<0.05; ep<0.01.
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Furthermore the doubling time of tumour cells in a small
population (liver micrometastases) is often shorter than in a
larger population (s.c. growing tumour), and therefore
micrometastases should be more sensitive to anticancer drugs
than larger primary tumours (Schabel, 1975). We have to
consider, however, that FAA, in contrast to most other
antitumour agents, does not cause detectable perturbation in
the cell cycle (Capalongo et al., 1987) and is very effective
against slow-growing mouse tumours. Therefore it is unlikely
that the preferential activity of FAA against small liver
tumour deposits compared to a s.c. growing tumour is due
to kinetic factors.
Recently it was suggested that FAA antitumour activity is
mediated through the activation of natural killer (NK) cells
(Ching & Baguley, 1987; Wiltrout, 1987). Injection of FAA
i.v. augmented NK activity in the lung, and especially in the
spleen and liver of mice (Wiltrout, 1987). NK cells have been
described as playing an important role in control of the
metastatic spread of tumour cells. Low NK activity in
rodents has been associated with an increase in experimental
metastasis formation in the lung (Barlozzari et al., 1985;
Hanna, 1982). We have found that i.s. injection of HCC cells
in anti-asialo GM1 serum pretreated nude mice (low NK
activity) led to a significant increase of liver tumour foci
(unpublished data). The possibility that the antineoplastic
effect of FAA observed in the spleen and liver of nude mice
results mainly from an immunomodulatory activity rather
than any direct antitumour activity remains for the moment
mere speculation.
The present findings show that FAA can be active on
HCC grafted in nude mice. Its preferential activity against
liver tumour formation makes this new agent potentially
useful in the therapy of micrometastases.
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